Baker McKenzie advised Swiss Similasan Group on the deal.
Similasan Group develops and produces homeopathic products and natural cosmetics. Originating in Switzerland in 1980, the Similasan brand has become popular across Europe and Similasan remedies are widely used and well-respected in North America.
Laboratoires Thea provides ophthalmology services and products. The Company offers treatments for glaucoma, allergy, dry eye, posterior segment, and infections, as well as research, innovation, and development services.
The Baker McKenzie team advising Similasan Group was led by Partner Lukas Glanzmann (Picture) and Alexander Fischer (Partner, Zurich), Alexander Blaeser (Senior Associate, Zurich), Daniel Kaelin (Associate, Zurich), Michael J. Fieweger (Partner, Chicago), Aidan Milstead (Associate, Chicago); Tax: Andrea Bolliger (Counsel, Zurich), Fabian Greutert (Associate, Zurich); Merger Control: Boris Wenger (Partner, Zurich), Roger Thomi (Associate, Zurich); and Intellectual Property: Julia Schieber (Senior Associate, Zurich).
Involved fees earner: Alexander Blaeser – Baker McKenzie; Andrea Bolliger – Baker McKenzie; Michael Fieweger – Baker McKenzie; Alexander Fischer – Baker McKenzie; Lukas Glanzmann – Baker McKenzie; Fabian Greutert – Baker McKenzie; Daniel Kaelin – Baker McKenzie; Aidan Milstead – Baker McKenzie; Julia Schieber – Baker McKenzie; Roger Thomi – Baker McKenzie; Boris Wenger – Baker McKenzie;
Law Firms: Baker McKenzie;
Clients: Swiss Similasan Group;